New hope for rare sinus cancer: combined therapy shows promise
NCT ID NCT07449949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment plan for adults with a rare cancer of the nasal and sinus cavities called rhabdomyosarcoma. The plan involves chemotherapy and radiation before and after surgery. The goal is to see if this approach can shrink tumors and improve survival. The study will enroll 43 people who have not been treated before.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vincristine, Actinomycin D, Epirubicin, Cisplatin, Cyclophosphamide, and radiation therapy
- What this could lead to
- If successful, this could provide a standard treatment approach for a rare cancer that currently lacks established guidelines.
- What could go wrong
- This is a small, single-arm study with only 43 participants, so results may not apply to all patients. The treatment involves strong chemotherapy and radiation, which can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 43 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study was conducted in patients with primary pathologically confirmed as rhabdomyosarcoma of the nasal cavity and paranasal sinuses without distant metastasis(subjects must have a measurable tumor lesion at baseline).
- Ages
-
18 to 70 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: 18-70 years old, gender not limited. * Pathologically confirmed as rhabdomyosarcoma of the nasal cavity and paranasal sinuses. * First-time treatment patients. * Distant metastasis was ruled out through a comprehensive physical examination. * Cases that met the inclusion criteria after joint discussion with rhinologists. * Expected survival period ≥6 months. * ECOG score: 0-2. Exclusion Criteria: * Patients whose distant metastasis has been clearly identified. * Previously, chemotherapy, immunotherapy or biological targeted therapy has been applied to the target lesion; Patients whose target lesions have received radiotherapy or surgery (excluding biopsy). * Functional impairment of vital organs
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORR are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
EENT hospital of Fudan University
Shanghai, China, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.